ClinicalTrials.gg
RecruitingNCT07376512EVpredictUpdated Oct 26, 2026

Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis

An observational study in Non-Small Cell Lung Cancer and Melanoma (Skin Cancer), sponsored by Centre Georges Francois Leclerc. Recruiting at 5 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Centre Georges Francois Leclerc · Observational

How we know

Updated Oct 26, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
378
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 875 studies in Carcinoma, Non-Small-Cell Lung with a site in France — 170 open to participants now, 327 under way, 105 of them phase 3. Carcinoma, Non-Small-Cell Lung · France.

Planned enrollment
22nd of 104
378 · median 151
Started
2026
with 34 others
Observational
104 of 875
26 open now
Primary completion
2030-11
later than 298 of 326 live
Registered
851st of 875
by date

Among the 875 studies in Carcinoma, Non-Small-Cell Lung with a site in France, this one is the 22nd largest by planned enrollment of the 104 observational ones that give a count, is one of 35 that started in 2026, is one of 104 observational ones, reaches primary completion later than 298 of the 326 other live ones, and was the 851st registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

170 of the 875 studies in Carcinoma, Non-Small-Cell Lung with a site in France are open now. Recruiting first, the newest first:

164 more — sign in →

All 170 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 875 studies in Carcinoma, Non-Small-Cell Lung with a site in France, or all of them as a file.
02

Study summary

The objective of this prospective multicenter study is to evaluate whether the analysis of immunological biomarkers present in circulating extracellular vesicles is associated with the response to anti-PD-1/PD-L1 treatments in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) or unresectable melanoma.

Patients will receive standard-of-care treatment and will be followed according to routine clinical practice. The study involves the collection of four study-specific blood samples at different time points during follow-up, as well as the collection of standard immunohistochemistry results, thoraco-abdomino-pelvic CT scans, and tumor DNA genotyping analyses performed as part of routine care.

The study aims to determine:

  • whether baseline biomarkers in extracellular vesicles are associated with response to anti-PD-1/PD-L1 treatment,
  • how these biomarkers change over the course of treatment, and
  • to provide exploratory data for the development of predictive immunological response signatures.
Read the detailed description

Immune checkpoint inhibitors (anti-PD-1/PD-L1) have become standard treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC) or melanoma. However, not all patients respond to these therapies, and current biomarkers are imperfect.

Circulating extracellular vesicles (EVs) are nanovesicles derived from tumor and immune cells, carrying proteins, nucleic acids, and lipids. They represent an accessible and stable source of immunological biomarkers, allowing monitoring of the tumor microenvironment without additional invasive procedures.

This prospective multicenter study aims to determine, in a prospective cohort of patients with locally advanced or metastatic lung cancer or melanoma, the impact of baseline immune biomarkers present in extracellular vesicles on response to anti-PD-(L)1 therapy

Secondary objectives have also been defined :

  • To evaluate the association between longitudinal changes in EV-associated immune biomarkers during follow-up and response to anti-PD-(L)1 therapy.
  • To develop a predictive score (immune signature) of response to anti-PD-(L)1 therapy by combining baseline EV-associated immune biomarkers.
  • To stratify analyses by tumor type (NSCLC versus melanoma) to determine whether tumor-specific characteristics influence the predictive performance of the identified immune signature.
  • To obtain preliminary evidence on the contribution of EV-associated biomarkers to the prediction of primary or secondary resistance to anti-PD-(L)1 therapy.
  • In the NSCLC cohort, to compare the predictive performance of the EV-based score with that of a score based solely on the tumor expression (assessed on biopsy specimens) of immunosuppressive proteins, without incorporating EV-associated biomarkers, for predicting best overall response (BOR) at 6 months.
  • To explore EV-derived miRNA profiles in responders and non-responders.
  • In each cohort, to compare the predictive performance of the EV-based score with that of a score integrating tumor mutational biomarkers derived from ctDNA and/or tumor tissue DNA for predicting BOR at 6 months.
  • To evaluate PFS, including PFS at 6 and 12 months, as well as median PFS.
  • To establish a prospective plasma biobank from patients treated with anti-PD-(L)1 therapies for future retrospective analyses following completion of the EVpredict study in the field of cancer immunology

Study procedures for participants include:

  • Blood sample collection: Four study-specific blood draws performed during standard treatment or tumor assessment visits (baseline, 2nd administration, first evaluation, second evaluation).
  • Collection of additional information: Standard immunohistochemistry results thoraco-abdomino-pelvic CT scans; circulating or tumor DNA genotyping analyses.
  • Clinical follow-up: Conducted according to routine care standards, with no changes to treatment or additional study-specific visits.
03

Conditions studied

  • Non-Small Cell Lung Cancer
  • Melanoma (Skin Cancer)

Keywords

  • standard treatment with anti-PD-(L)1 monotherapy or combination therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with non-small cell lung cancer (NSCLC) or melanoma, locally advanced or metastatic, and unresectable. For all patients, first-line standard treatment will be based on standard care with an anti-PD-(L)1 therapy, either as monotherapy or in combination (with other immune checkpoint inhibitors or chemotherapy). Standard treatments are defined by the approved indications (marketing authorizations) in France.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • confirmed diagnosis of non-small cell lung cancer (NSCLC) or locally advanced/ unresectable melanoma.
  • Patient scheduled to initiate anti-PD-(L)1 therapy, either as monotherapy or in combination (other , chemotherapy, etc.).
  • Baseline tumor assessment performed within 28 days prior to enrollment (CT scan of thorax, abdomen, and pelvis) with at least one according to 1.1 criteria.
  • >6 months.
  • (ECOG) performance status of 0-2 at enrollment.
  • Patient able to provide and comply with study procedures.
  • Patient covered by a social security system or equivalent.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with immunotherapy.
  • Presence of EGFR or ALK mutation (applicable only to the lung cohort).
  • Presence of another synchronous .
  • Diagnosis of uveal melanoma.
  • Treatment with systemic , including within 28 days prior to enrollment, or >10 mg/day, including within 14 days prior to enrollment.
  • Disease not measurable according to 1.1 criteria.
  • Positive serology for , , or .
  • Pregnant or breastfeeding women.
  • Inability to comply with study follow-up and visits for geographic, social, or psychological reasons.
  • Individuals deprived of liberty or under legal guardianship (including curatorship).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
378 participants (estimated)
Patient registry
No

Groups and cohorts

  • Advanced NSCLC or Melanoma - Anti-PD-(L)1 Therapy

    This cohort includes patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) or inoperable melanoma who are receiving standard-of-care anti-PD-1 or anti-PD-L1 therapy, either as monotherapy or in combination with other approved therapies. Participants will follow standard clinical management, and study-specific procedures include four blood draws for extracellular vesicle (EV) analysis at baseline and during follow-up, collection of standard immunohistochemistry results (PD-1, PD-L1, CTLA-4, Tim-3, LAG-3, TIGIT), thoraco-abdominopelvic CT imaging, and tumor DNA genotyping performed as part of routine care.

06

What researchers measure

Primary outcomes

  1. Target protein levels in plasma-derived extracellular vesicles (EVs) measured by multiplex ELISA before treatment

    Treatment response assessed as Best Overall Response (BOR: complete or partial response per RECIST 1.1) within 6 months.

    Time frame: 6 months from treatment initiation

Secondary outcomes

  1. Association of EV-Associated Target Protein Concentrations With Best Overall Response at 6 Months

    Time frame: Baseline to 6 months after treatment initiation

  2. Development of a Predictive Score Based on Baseline EV-Associated Biomarkers for Best Overall Response at 6 Months

    Time frame: Baseline to 6 months after treatment initiation

  3. Predictive Performance of the EV-Based Score for Best Overall Response

    Predictive performance will be assessed using the area under the receiver operating characteristic curve (AUC) and, following score dichotomization, sensitivity and specificity. Performance for predicting BOR will be evaluated in the overall cohort and separately in the NSCLC and melanoma cohorts.

    Time frame: At 6 months after treatment initiation

  4. EV-Associated Target Protein Concentrations in Non-Responders to Anti-PD-(L)1 Therapy

    Analysis of target protein concentrations in EVs at baseline and during follow-up in non-responders according to RECIST 1.1 criteria. These preliminary data will provide an initial assessment of the feasibility of a future clinical trial evaluating the therapeutic benefit of EV analysis for guiding treatment decisions regarding immune checkpoint inhibitor combination therapies in patients with solid tumors.

    Time frame: Baseline to 6 months after treatment initiation

  5. Comparison of the Predictive Performance of Tumor Immunohistochemistry and the EV-Based Score in the NSCLC Cohort

    In the NSCLC cohort, immunohistochemical (IHC) analysis of target protein expression (including PD-L1) will be performed on diagnostic tumor biopsy specimens. The predictive performance of this approach will be compared with that of the EV-based score using receiver operating characteristic (ROC) curve analyses and the AUC.

    Time frame: Baseline to 6 months after treatment initiation

  6. Comparison of EV-Derived miRNA Expression Profiles Between Responders and Non-Responders

    EV-derived miRNA expression profiles at baseline and during follow-up will be analyzed by RT-qPCR and compared between responders and non-responders.

    Time frame: Baseline to 6 months after treatment initiation

  7. Comparison of the Predictive Performance of Tumor DNA Biomarkers and the EV-Based Score

    Analysis of tumor DNA, including ctDNA and/or tumor tissue DNA, will be performed by next-generation sequencing (NGS) at diagnosis and at disease progression. The predictive performance of these biomarkers will be compared with that of the EV-based score using ROC curve analyses and the corresponding AUC.

    Time frame: At diagnosis and at disease progression; BOR assessed at 6 months after treatment initiation

  8. Progression-Free Survival (PFS) at 6 and 12 Months and Median PFS

    PFS will be defined as the time from study inclusion to disease progression, as assessed according to RECIST 1.1 criteria, or death from any cause, whichever occurs first. Patients who are alive without documented progression will be censored at the date of their last known follow-up. Median PFS, as well as PFS rates at 6 and 12 months, will be described

    Time frame: From the date of enrollment in the study until the first occurrence of disease progression or death, or up to 12 months after enrollment

  9. Storage of Residual Plasma Samples for Future Retrospective Analyses

    Residual plasma samples remaining after completion of the study-specific analyses will be stored for future retrospective analyses in participants who have provided consent for biological sample collection. Additional and more in-depth analyses of biomarkers of interest may be performed based on the results generated during the EVpredict study.

    Time frame: Up to 15 years after the end of the study

07

Study locations

2 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2030, 48 months later.

Of 358 non-industry observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 48 months is below that.

Counting every sponsor, half of 500 studies reached it within 55 months; a quarter within 35 and three quarters within 83.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: start Mar 2026 → Nov 2026, primary completion Mar 2029 → Nov 2030 and completion Mar 2030 → Nov 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2026
First posted
Jan 29, 2026
StartEst.
Nov 1, 2026was Mar 2026
Primary completionEst.
Nov 1, 2030was Mar 2029
CompletionEst.
Nov 1, 2030was Mar 2030
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
5 sites changed recruiting status (3 now not yet recruiting, 2 now recruiting)
Show 5 sites
  • CHU Besançon - Service Dermatologie · Besançon, Franceno status→Not yet recruiting
  • CHU Besançon - Service Pneumologie Oncologie Thoracique · Besançon, Franceno status→Not yet recruiting
  • Centre Georges-François Leclerc · Dijon, Franceno status→Recruiting
  • CHU Dijon - Service Oncologie Médicale · Dijon, Franceno status→Recruiting
  • Centre Leon Berard - Service Oncologie Médicale · Lyon, Franceno status→Not yet recruiting
Oct 26, 2026
Start date
Mar 1, 2026→Nov 1, 2026
Oct 26, 2026
Primary completion
Mar 1, 2029→Nov 1, 2030
Oct 26, 2026
Study completion
Mar 1, 2030→Nov 1, 2030
Oct 26, 2026
Secondary outcomes
9 added
What changed in the outcomes
  • AddedAssociation of EV-Associated Target Protein Concentrations With Best Overall Response at 6 MonthsTime frame: Baseline to 6 months after treatment initiation
  • AddedDevelopment of a Predictive Score Based on Baseline EV-Associated Biomarkers for Best Overall Response at 6 MonthsTime frame: Baseline to 6 months after treatment initiation
  • AddedPredictive Performance of the EV-Based Score for Best Overall ResponseTime frame: At 6 months after treatment initiation
  • AddedEV-Associated Target Protein Concentrations in Non-Responders to Anti-PD-(L)1 TherapyTime frame: Baseline to 6 months after treatment initiation
  • AddedComparison of the Predictive Performance of Tumor Immunohistochemistry and the EV-Based Score in the NSCLC CohortTime frame: Baseline to 6 months after treatment initiation
  • AddedComparison of EV-Derived miRNA Expression Profiles Between Responders and Non-RespondersTime frame: Baseline to 6 months after treatment initiation
  • AddedComparison of the Predictive Performance of Tumor DNA Biomarkers and the EV-Based ScoreTime frame: At diagnosis and at disease progression; BOR assessed at 6 months after treatment initiation
  • AddedProgression-Free Survival (PFS) at 6 and 12 Months and Median PFSTime frame: From the date of enrollment in the study until the first occurrence of disease progression or death, or up to 12 months after enrollment
  • AddedStorage of Residual Plasma Samples for Future Retrospective AnalysesTime frame: Up to 15 years after the end of the study
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    5 sites changed recruiting status (3 now not yet recruiting, 2 now recruiting)
    Show 5 sites
    • CHU Besançon - Service Dermatologie · Besançon, Franceno status→Not yet recruiting
    • CHU Besançon - Service Pneumologie Oncologie Thoracique · Besançon, Franceno status→Not yet recruiting
    • Centre Georges-François Leclerc · Dijon, Franceno status→Recruiting
    • CHU Dijon - Service Oncologie Médicale · Dijon, Franceno status→Recruiting
    • Centre Leon Berard - Service Oncologie Médicale · Lyon, Franceno status→Not yet recruiting
    Start date Mar 1, 2026→Nov 1, 2026
    Primary completion Mar 1, 2029→Nov 1, 2030
    Study completion Mar 1, 2030→Nov 1, 2030
    Secondary outcomes 9 added
    What changed in the outcomes
    • AddedAssociation of EV-Associated Target Protein Concentrations With Best Overall Response at 6 MonthsTime frame: Baseline to 6 months after treatment initiation
    • AddedDevelopment of a Predictive Score Based on Baseline EV-Associated Biomarkers for Best Overall Response at 6 MonthsTime frame: Baseline to 6 months after treatment initiation
    • AddedPredictive Performance of the EV-Based Score for Best Overall ResponseTime frame: At 6 months after treatment initiation
    • AddedEV-Associated Target Protein Concentrations in Non-Responders to Anti-PD-(L)1 TherapyTime frame: Baseline to 6 months after treatment initiation
    • AddedComparison of the Predictive Performance of Tumor Immunohistochemistry and the EV-Based Score in the NSCLC CohortTime frame: Baseline to 6 months after treatment initiation
    • AddedComparison of EV-Derived miRNA Expression Profiles Between Responders and Non-RespondersTime frame: Baseline to 6 months after treatment initiation
    • AddedComparison of the Predictive Performance of Tumor DNA Biomarkers and the EV-Based ScoreTime frame: At diagnosis and at disease progression; BOR assessed at 6 months after treatment initiation
    • AddedProgression-Free Survival (PFS) at 6 and 12 Months and Median PFSTime frame: From the date of enrollment in the study until the first occurrence of disease progression or death, or up to 12 months after enrollment
    • AddedStorage of Residual Plasma Samples for Future Retrospective AnalysesTime frame: Up to 15 years after the end of the study
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07376512
Lead sponsor
Centre Georges Francois Leclerc
Responsible party
Sponsor
First posted
Jan 29, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Nov 1, 2030 (estimated)
Completion
Nov 1, 2030 (estimated)
Last update
Oct 26, 2026

Study contacts

Courèche CK KADERBHAI, Doctor
Contact
cgkaderbhai@cgfl.fr
03 80 73 75 28 ext. +33
Anne-Laure ALR REROLE, Project manager
Contact
arerole@cgfl.fr
03 45 34 88 46 ext. +33
Jessica JG GOBBO, Clinical Research Scientist
study chair · Centre Georges François Leclerc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion